Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab [5]

Bone Marrow Transplantation

Volumn 41, Issue 6, 2008, Pages 595-596

  Benson, D M ^a,b   Smith, M K ^b   Krugh, D ^a   Devine, S M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; FOLIC ACID; IRON; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; APLASTIC ANEMIA; BONE MARROW BIOPSY; CANCER STAGING; CASE REPORT; CHEMOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; GENERAL CONDITION IMPROVEMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LARGE CELL LYMPHOMA; LETTER; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETICULOCYTE COUNT; SALVAGE THERAPY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HEMOGLOBINS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RED-CELL APLASIA, PURE; REMISSION INDUCTION; RETICULOCYTE COUNT; TIME FACTORS; TREATMENT OUTCOME;

EID: 41549115499     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705945     Document Type: Letter

References (11)

1. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C et al. Treatment of refractory chronic GVHD with rituximab: A GITMO study. Bone Marrow Transplant 2007; 40: 273-277.
2. Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia. Haematologica 2005; 90 (Suppl): ECR33.
3. Yamaguchi M, Sakai K, Murata R, Ueda M. Treatment of pure red cell aplasia after ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-varsus-host disease. Bone Marrow Transplant 2002; 30: 539-541.
4. Grigg AP, Juneja SK. Pure red cell aplasia with the onset of graft versus host disease. Bone Marrow Transplant 2003; 32: 1099-1101.
5. Zhu KE, Li JP, Zhang T, Zhong J, Chen J. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology 2007; 12: 117-121.
6. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonk LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104: 2603-2606.
7. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505-511.
8. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756-762.
9. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 180-185.
10. Eisenberg R, Looney RJ. The therapeutic potential of antiCD20. What do B cells do? Clin Immunol 2005; 117: 207-213.
11. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435-454.